Advertisement

Annals of Hematology

, Volume 95, Issue 5, pp 707–718 | Cite as

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)

  • Iris Appelmann
  • Stephan Kreher
  • Stefani Parmentier
  • Hans-Heinrich Wolf
  • Guido Bisping
  • Martin Kirschner
  • Frauke Bergmann
  • Kristina Schilling
  • Tim H. Brümmendorf
  • Petro E. Petrides
  • Andreas Tiede
  • Axel Matzdorff
  • Martin Griesshammer
  • Hanno Riess
  • Steffen KoschmiederEmail author
Review Article

Abstract

Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN) comprise a heterogeneous group of chronic hematologic malignancies. The quality of life, morbidity, and mortality of patients with MPN are primarily affected by disease-related symptoms, thromboembolic and hemorrhagic complications, and progression to myelofibrosis and acute leukemia. Major bleeding represents a common and important complication in MPN, and the incidence of such bleeding events will become even more relevant in the future due to the increasing disease prevalence and survival of MPN patients. This review discusses the causes, differential diagnoses, prevention, and management of bleeding episodes in patients with MPN, aiming at defining updated standards of care in these often challenging situations.

Keywords

MPN Myeloproliferative neoplasms Bleeding Hemorrhage Management Essential thrombocythemia Polycythemia vera Review 

Notes

Compliance with ethical standards

Conflict of interest

GB received honoraria and travel grants from Bristol Myers Squibb, Novartis, Sanofi, and Merck.

KS is a member of the Advisory Board of Novo Nordisk and a travel support of Bayer.

TB received honoraria for participation in satellite symposia and advisory boards and research support from Novartis.

AT received research funding, honoraria for consultancy, and travel support from Baxter, Bayer, Biotest, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, and Pfizer.

AM is a consultant of Leo Pharma and Roche, has equity ownership of Bayer and Roche, and a recipient of research funding from Leo Pharma; honoraria and travel grants from Amgen, Aspen Germany, Boehringer Ingelheim, Behring, Bristol-Myers Squibb, GlaxoSmithKline, Leo Pharma, Novartis, and Roche (patents and royalties: not applicable); and membership on an entity’s Board of Directors or advisory committees of Bristol-Myers Squibb and Leo Pharma.

HR is a member of Consultancy and Advisory Boards of Aspen, Baxalta, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Leo-Pharma, Novartis, Pfizer, Sanofi, and Shire.

SK a member of Consultancy and Advisory Boards of Ariad, AOP, Baxalta, Bristol-Myers Squibb, CTI, Novartis, Pfizer, and Sanofi. He received research funding (Novartis and Novartis Foundation) and honoraria and travel grants (Ariad, Alexion, AOP, Baxalta, Bristol-Myers Squibb, Celgene, CTI, Novartis, Pfizer, Sanofi, Shire).

References

  1. 1.
    Swerdlow SH, International Agency for Research on C, World Health O (2008) WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on CancerGoogle Scholar
  2. 2.
    Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6(4):372–375PubMedGoogle Scholar
  3. 3.
    Abdel-Wahab O (2011) Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 18(2):117–123PubMedCrossRefGoogle Scholar
  4. 4.
    Abdel-Wahab O, Pardanani A, Patel J et al (2011) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25(7):1200–1202PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Etheridge SL, Roh ME, Cosgrove ME et al (2014) JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci U S A 111(6):2295–2300PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390PubMedCrossRefGoogle Scholar
  7. 7.
    Rampal R, Al-Shahrour F, Abdel-Wahab O et al (2014) Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123(22):e123–133PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Rampal R, Levine RL (2014) A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Best Pract Res Clin Haematol 27(2):83–93PubMedCrossRefGoogle Scholar
  9. 9.
    Kilpivaara O, Levine RL (2008) JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22(10):1813–1817PubMedCrossRefGoogle Scholar
  10. 10.
    Kander EM, Raza S, Zhou Z et al (2015) Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102(5):587–593PubMedCrossRefGoogle Scholar
  11. 11.
    Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45PubMedCrossRefGoogle Scholar
  12. 12.
    Budde U, van Genderen PJ (1997) Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 23(5):425–431PubMedCrossRefGoogle Scholar
  13. 13.
    Tefferi A, Smock KJ, Divgi AB (2010) Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. Am J Hematol 85(7):545PubMedCrossRefGoogle Scholar
  14. 14.
    Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS (1986) Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 68(6):1213–1217PubMedGoogle Scholar
  15. 15.
    Fabris F, Casonato A, del Ben GM, De Marco L, Girolami A (1986) Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 63(1):75–83PubMedCrossRefGoogle Scholar
  16. 16.
    Mohri H (1987) Acquired von Willebrand disease in patients with polycythemia rubra vera. Am J Hematol 26(2):135–146PubMedCrossRefGoogle Scholar
  17. 17.
    Ruggeri M, Rodeghiero F, Tosetto A et al (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111(2):666–671PubMedCrossRefGoogle Scholar
  18. 18.
    Budde U, Bergmann F, Michiels JJ (2002) Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 28(2):227–238PubMedCrossRefGoogle Scholar
  19. 19.
    Tiede A, Klamroth R, Scharf RE, et al (2014) Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. BloodGoogle Scholar
  20. 20.
    Tiede A, Rand JH, Budde U, Ganser A, Federici AB (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777–6785PubMedCrossRefGoogle Scholar
  21. 21.
    Tiede A, Priesack J, Werwitzke S et al (2008) Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 6(4):569–576PubMedCrossRefGoogle Scholar
  22. 22.
    Tefferi A (2012) Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(3):285–293PubMedGoogle Scholar
  23. 23.
    Chim CS, Kwong YL, Lie AK et al (2005) Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 165(22):2651–2658PubMedCrossRefGoogle Scholar
  24. 24.
    Michiels JJ, De Raeve H, Berneman Z et al (2006) The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 32(4 Pt 2):307–340PubMedCrossRefGoogle Scholar
  25. 25.
    Beer PA, Erber WN, Campbell PJ, Green AR (2011) How I treat essential thrombocythemia. Blood 117(5):1472–1482PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Petro E. Petrides GMB, Heinz Gisslinger, Martin Grießhammer, Eva Lengfelder (2014) Essentielle (oder primaere) Thrombozythaemie. DGHO Leitlinien OnkopediaGoogle Scholar
  27. 27.
    Federici AB, Rand JH, Bucciarelli P et al (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84(2):345–349PubMedGoogle Scholar
  28. 28.
    Castaman G, Tosetto A, Federici AB, Rodeghiero F (2011) Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 105(4):647–654PubMedCrossRefGoogle Scholar
  29. 29.
    Laffan MA, Lester W, O’Donnell JS et al (2014) The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British committee for standards in haematology. Br J Haematol 167(4):453–465PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Trigg DE, Stergiotou I, Peitsidis P, Kadir RA (2012) A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 18(1):25–33PubMedCrossRefGoogle Scholar
  31. 31.
    Pasi KJ, Collins PW, Keeling DM et al (2004) Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 10(3):218–231PubMedCrossRefGoogle Scholar
  32. 32.
    Federici AB (2005) Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 16(Suppl 1):S17–21PubMedCrossRefGoogle Scholar
  33. 33.
    Mannucci PMPAK PA, Schulman S, Di Paola J, Schneppenheim R, Cox Gill J (2013) Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand’s disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion 4:533–540Google Scholar
  34. 34.
    Franchini M, Veneri D, Lippi G (2006) The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinolysis 17(8):615–619PubMedCrossRefGoogle Scholar
  35. 35.
    Leissinger C, Becton D, Cornell C Jr, Cox GJ (2001) High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 7(3):258–266PubMedCrossRefGoogle Scholar
  36. 36.
    Barbui T, Carobbio A, Cervantes F et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782PubMedCrossRefGoogle Scholar
  37. 37.
    Cox SR, VanderLugt JT, Gumbleton TJ, Smith RB (1987) Relationships between thromboxane production, platelet aggregability, and serum concentrations of ibuprofen or flurbiprofen. Clin Pharmacol Ther 41(5):510–521PubMedCrossRefGoogle Scholar
  38. 38.
    Cronberg S, Wallmark E, Soderberg I (1984) Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 33(2):155–159PubMedCrossRefGoogle Scholar
  39. 39.
    O’Brien JR (1968) Effect of anti-inflammatory agents on platelets. Lancet 1(7548):894–895PubMedCrossRefGoogle Scholar
  40. 40.
    Favaloro EJ, Bukuya M, Martinelli T et al (2002) A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 87(3):466–476PubMedGoogle Scholar
  41. 41.
    Harrison P, Mackie I, Mumford A et al (2011) Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 155(1):30–44PubMedCrossRefGoogle Scholar
  42. 42.
    Fleming JS, Buyniski JP (1979) A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 15(3–4):373–388PubMedCrossRefGoogle Scholar
  43. 43.
    Gisslinger H, Gotic M, Holowiecki J et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720–1728PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Finazzi G (2012) How to manage essential thrombocythemia. Leukemia 26(5):875–882PubMedCrossRefGoogle Scholar
  45. 45.
    Steurer M, Gastl G, Jedrzejczak WW et al (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101(10):2239–2246PubMedCrossRefGoogle Scholar
  46. 46.
    Moore SF, Hunter RW, Harper MT et al (2013) Dysfunction of the PI3 kinase/Rap1/integrin alpha(IIb)beta(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia. Blood 121(7):1209–1219PubMedCrossRefGoogle Scholar
  47. 47.
    Lamrani L, Lacout C, Ollivier V et al (2014) Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood 124(7):1136–1145PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Afshar-Kharghan V, Lopez JA, Gray LA et al (2004) Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 15(1):21–24PubMedCrossRefGoogle Scholar
  49. 49.
    Tefferi A, Lasho TL, Jimma T et al (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87(1):25–33PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Tam CS, Nussenzveig RM, Popat U et al (2008) The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 112(5):1628–1637PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Talpaz M, Paquette R, Afrin L et al (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6(1):81PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Bjorn ME, Holmstrom MO, Hasselbalch HC (2015) Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leuk Lymphoma. 2015:1–4Google Scholar
  53. 53.
    Ho PJ, Marlton P, Tam C et al (2015) Practical management of myelofibrosis with ruxolitinib. Intern Med J 45(12):1221–1230PubMedCrossRefGoogle Scholar
  54. 54.
    Santos FP, Tam CS, Kantarjian H et al (2014) Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 55(1):121–127PubMedCrossRefGoogle Scholar
  55. 55.
    Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798PubMedCrossRefGoogle Scholar
  57. 57.
    Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807PubMedCrossRefGoogle Scholar
  58. 58.
    Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A (2015) Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia 29(2):498–500PubMedCrossRefGoogle Scholar
  59. 59.
    Cervantes F, Vannucchi AM, Kiladjian JJ et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047–4053PubMedCrossRefGoogle Scholar
  60. 60.
    Harrison C, Mesa R, Ross D et al (2013) Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 6(5):511–523PubMedCrossRefGoogle Scholar
  61. 61.
    Verstovsek S, Gotlib J, Gupta V et al (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13–21PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Verstovsek S, Mesa RA, Gotlib J et al (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865–1871PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Verstovsek S, Passamonti F, Rambaldi A et al (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513–520PubMedCrossRefGoogle Scholar
  64. 64.
    Kaufman RM, Djulbegovic B, Gernsheimer T et al (2015) Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162(3):205–213PubMedCrossRefGoogle Scholar
  65. 65.
    Kumar A, Mhaskar R, Grossman BJ et al (2015) Platelet transfusion: a systematic review of the clinical evidence. Transfusion 55(5):1116–1127, quiz 1115PubMedCrossRefGoogle Scholar
  66. 66.
    De Stefano V, Rossi E, Za T, Chiusolo P, Leone G (2008) The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal. Thromb Haemost 99(6):1121PubMedGoogle Scholar
  67. 67.
    Mahan CE, Liu Y, Turpie AG et al (2014) External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 112(4):692–699PubMedCrossRefGoogle Scholar
  68. 68.
    Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232PubMedCrossRefGoogle Scholar
  69. 69.
    Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33PubMedCrossRefGoogle Scholar
  70. 70.
    De Stefano V, Za T, Rossi E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372–380PubMedCrossRefGoogle Scholar
  71. 71.
    Papadakis E, Hoffman R, Brenner B (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 24(6):227–232PubMedCrossRefGoogle Scholar
  72. 72.
    Bachleitner-Hofmann T, Grumbeck E, Gisslinger H (2003) Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. Thromb Res 112(4):229–232PubMedCrossRefGoogle Scholar
  73. 73.
    Kreher S, Ochsenreither S, Trappe RU et al (2014) Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the haemostasis working party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol 93(12):1953–1963PubMedCrossRefGoogle Scholar
  74. 74.
    Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest P (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):257S–298SPubMedCrossRefGoogle Scholar
  75. 75.
    Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8):e75–87PubMedCrossRefGoogle Scholar
  76. 76.
    Ruff CT, Giugliano RP, Braunwald E, Antman EM (2014) New oral anticoagulants in patients with atrial fibrillation—authors’ reply. Lancet 384(9937):25–26PubMedCrossRefGoogle Scholar
  77. 77.
    Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962PubMedCrossRefGoogle Scholar
  78. 78.
    van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975PubMedCrossRefGoogle Scholar
  79. 79.
    Prins MH, Lensing AW (2013) Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J 11(1):13PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Prins MH, Lensing AW, Bauersachs R et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11(1):21PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134(6):1214–1219PubMedCrossRefGoogle Scholar
  82. 82.
    Hanken H, Grobe A, Heiland M, et al (2015) Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral InvestigGoogle Scholar
  83. 83.
    Andras A, Sala Tenna A, Crawford F (2012) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev; 10:CD002001Google Scholar
  84. 84.
    Laporte S, Bertoletti L, Romera A, Mismetti P, de Llano LA P, Meyer G (2012) Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res 130(6):853–858PubMedCrossRefGoogle Scholar
  85. 85.
    Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153PubMedCrossRefGoogle Scholar
  86. 86.
    Liote F, Yeni P, Teillet-Thiebaud F et al (1991) Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature. Am J Med 90(1):111–117PubMedCrossRefGoogle Scholar
  87. 87.
    Lopez-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C (1991) Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 85(4):184–188PubMedCrossRefGoogle Scholar
  88. 88.
    Anger BR, Seifried E, Scheppach J, Heimpel H (1989) Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 67(16):818–825PubMedCrossRefGoogle Scholar
  89. 89.
    Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012:571–581PubMedGoogle Scholar
  90. 90.
    Falanga A, Marchetti M, Russo L (2012) Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol 24(6):702–710PubMedCrossRefGoogle Scholar
  91. 91.
    Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF (2010) Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126(3):238–242PubMedCrossRefGoogle Scholar
  92. 92.
    Panova-Noeva M, Marchetti M, Buoro S et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118(9):2599–2601PubMedCrossRefGoogle Scholar
  93. 93.
    Lee WM, Stravitz RT, Larson AM (2012) Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011. Hepatology 55(3):965–967PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Stravitz RT, Kramer AH, Davern T et al (2007) Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 35(11):2498–2508PubMedCrossRefGoogle Scholar
  95. 95.
    Hultcrantz M, Wilkes SR, Kristinsson SY et al (2015) Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol 33(20):2288–2295PubMedCrossRefGoogle Scholar
  96. 96.
    Taylor FB Jr, Toh CH, Hoots WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327–1330PubMedGoogle Scholar
  97. 97.
    Biss T, Crossman L, Neilly I, Hanley J (2003) An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage. Haemophilia 9(5):638–641PubMedCrossRefGoogle Scholar
  98. 98.
    Vener C, Artoni A, Boschetti C et al (2012) An acquired factor VIII inhibitor in a myeloproliferative neoplasm presenting with severe retroperitoneal hemorrhage. Leuk Lymphoma 53(11):2296–2298PubMedCrossRefGoogle Scholar
  99. 99.
    Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K (2012) Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation. J Blood Med 3:157–161PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Kremyanskaya M, Aledort L (2011) Acquired hemophilia: we now see it with myeloproliferative neoplasms. Am J Hematol 86(3):329–330PubMedCrossRefGoogle Scholar
  101. 101.
    Dentali F, Squizzato A, Appio L, Brivio L, Ageno W (2009) JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease. J Thromb Haemost 7(4):722–725PubMedCrossRefGoogle Scholar
  102. 102.
    Dentali F, Squizzato A, Brivio L et al (2009) JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617–5623PubMedCrossRefGoogle Scholar
  103. 103.
    Orr DW, Patel RK, Lea NC et al (2010) The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 31(12):1330–1336PubMedCrossRefGoogle Scholar
  104. 104.
    Yan M, Geyer H, Mesa R et al (2015) Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk 15(1):e1–5PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Bejanyan N, Tiu RV, Raza A et al (2012) A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer 118(16):3968–3976PubMedCrossRefGoogle Scholar
  106. 106.
    Link CS, Platzbecker U, Kroschinsky F et al (2013) Association of oesophageal varices and splanchnic vein thromboses in patients with JAK2-positive myeloproliferative neoplasms: presentation of two cases and data from a retrospective analysis. Case Rep Oncol 6(2):311–315PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Condat B, Pessione F, Hillaire S et al (2001) Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 120(2):490–497PubMedCrossRefGoogle Scholar
  108. 108.
    Koschmieder S, Koppelle A, Seifert H (2012) Ruxolitinib for myelofibrosis. N Engl J Med 366(21):2031–2032, author reply 2032–2034PubMedCrossRefGoogle Scholar
  109. 109.
    Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM (2000) Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 6(2):71–77PubMedCrossRefGoogle Scholar
  110. 110.
    Carter G, Goss A (2003) Tranexamic acid mouthwash—a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. Int J Oral Maxillofac Surg 32(5):504–507PubMedGoogle Scholar
  111. 111.
    Carter G, Goss A, Lloyd J, Tocchetti R (2003) Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. J Oral Maxillofac Surg 61(12):1432–1435PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Iris Appelmann
    • 1
  • Stephan Kreher
    • 2
  • Stefani Parmentier
    • 3
  • Hans-Heinrich Wolf
    • 4
  • Guido Bisping
    • 5
  • Martin Kirschner
    • 1
  • Frauke Bergmann
    • 6
  • Kristina Schilling
    • 7
  • Tim H. Brümmendorf
    • 1
  • Petro E. Petrides
    • 8
  • Andreas Tiede
    • 9
  • Axel Matzdorff
    • 10
  • Martin Griesshammer
    • 11
  • Hanno Riess
    • 2
  • Steffen Koschmieder
    • 1
    Email author
  1. 1.Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of MedicineRWTH Aachen UniversityAachenGermany
  2. 2.Department of Hematology and OncologyCharite BerlinBerlinGermany
  3. 3.Department of Hematology, Oncology, and Palliative MedicineRems-Murr-Klinikum WinnendenWinnendenGermany
  4. 4.Department of Internal Medicine IVMartin-Luther-University Halle-WittenbergHalle (Saale)Germany
  5. 5.Department of Medicine IMathias Spital RheineRheineGermany
  6. 6.Medizinisches Versorgungszentrum WagnerstibbeHannoverGermany
  7. 7.Department of Hematology and OncologyUniversity Hospital JenaJenaGermany
  8. 8.Hematology Oncology CentreLudwig Maximilians University of Munich Medical SchoolMunichGermany
  9. 9.Department of Haematology, Haemostasis, Oncology and Stem-Cell Transplantation, Hannover Medical SchoolHannoverGermany
  10. 10.Clinic for Internal Medicine II, Dept. of Hematology, OncologyAsklepios Clinic UckermarkSchwedt/OderGermany
  11. 11.Johannes Wesling Academic Medical CenterMindenGermany

Personalised recommendations